Effect of 1% sodium alendronate in the non-surgical treatment of periodontal intraosseous defects: a 6-month clinical trial 
Because of the previously demonstrated capacity of the periodontal tissues for regeneration 8 , there
has been increased interest in the mechanisms of periodontal wound healing and the biological factors and cells involved in this process 13 . , or combinations of procedures 13, 22 . However, some of these regenerative techniques have restricted predictability, high cost, bioactive molecules using vehicles known as carrier agents has an important role in tissue regenerative therapy 7 .
Biphosphonates (BPhs) are a group of bone metabolism mediators, presently used to treat osteoclast-mediated bone loss due to osteoporosis and other conditions 5, 9 . Due to their effects on the differentiation, activity, and apoptosis of osteoclasts, they slow down the rate of bone loss and increase the resistance to bone fracture 19 . Sodium alendronate (ALN), an aminobisphosphonate, acts as a potent inhibitor of bone resorption 4, 10 of ALN for hydroxyapatite, it has been suggested that the ALN drug complex is retained at the site of injection 12, 16 . In vitro studies demonstrated that 
Results
The present study included 20 participants (mean age 44.9 years old), the majority of whom were female (60%), whose proximal contralateral sites (n=40)
were analyzed. The majority of the sites selected for the topical application of either 1% ALN gel or a placebo gel were located on the lower posterior teeth (90%) ( Table 1 ).
The periodontal treatment produced improvements in the clinical parameters of the participants ( Table   2 ). The percentages of both BOP and PPD (4-6 mm Table 3 shows the comparative results of the primary outcome (CAL measurement) of the two treatment groups (1% ALN and placebo gels).
Although the PPD reductions in both treatments at the 6-month follow-up were similar, ALN application after scaling produced a greater CAL gain at the 3-month follow-up. This difference was also observed at the 6-month follow-up.
Bone measurements are shown in Table 4 , although study power was not higher than 80%. However, external validity is still a barrier to be overcome.
Additionally, it should be emphasized that ALN did not cause any local adverse events. This fact reinforces the advantages of its topical application over its systemic use, thus contributing to greater safety and better conformance of the individuals.
In the present study, the measurement of the interproximal bone defects was performed using the CBCT images acquired at the baseline and at 6 months mean bone height was observed in sites that received 
